SAN ANTONIO, January 07, 2026--bioAffinity's laboratory, Precision Pathology Laboratory Services, maintains accreditation from the College of American Pathologists ...
Remedy Cell, a clinical-stage biopharmaceutical company focused on the development of proprietary cell-derived therapies for fibrotic diseases, today announces the initiation of "a partially-blinded ...
Verona Pharma's ensifentrine is a first-in-class, inhaled, dual inhibitor of the enzymes PDE3 and PDE4, targeting both bronchodilation and inflammation. Positive Phase 3 results from the ENHANCE ...
Panelists discuss how idiopathic pulmonary fibrosis (IPF), a progressive and often fatal interstitial lung disease, presents significant clinical challenges due to its variable trajectory, limited ...
Severe SARS-CoV-2 infection often leads to development of acute respiratory distress syndrome (ARDS), with profound pulmonary patho-histological changes post-mortem. In this study, we utilized the ...
Emphysema is a chronic lung condition characterised by the destruction of alveolar walls. This pathophysiology involves damage that impairs the lungs' ability to recoil: decreasing airflow and causing ...
Researchers at Weill Cornell Medicine and New York-Presbyterian in New York have discovered that injecting mice with healthy pulmonary endothelial cells (ECs)—the cells that line the walls of blood ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback